published meta-analysis   sensitivity analysis   studies

convalescent plasma treatment in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsC3PO, 2020 5.02 [0.58; 43.27] CoV-Early (Gharbharan), 2022 1.01 [0.06; 16.25] 2.75[0.50; 15.09]C3PO, 2020, CoV-Early (Gharbharan), 202220%927moderatenot evaluable deathsdetailed resultsC3PO, 2020 5.02 [0.58; 43.27] CONV-ERT, 2021 0.20 [0.01; 4.07] CoV-Early (Gharbharan), 2022 1.01 [0.06; 16.25] 1.28[0.20; 8.11]C3PO, 2020, CONV-ERT, 2021, CoV-Early (Gharbharan), 2022333%1,275lownot evaluable hospitalization or deathdetailed resultsC3PO, 2020 0.91 [0.63; 1.33] 0.91[0.63; 1.33]C3PO, 202010%511NAnot evaluable hospitalizationdetailed resultsC3PO, 2020 0.88 [0.57; 1.34] CONV-ERT, 2021 1.05 [0.78; 1.41] CoV-Early (Gharbharan), 2022 0.61 [0.28; 1.33] 0.95[0.75; 1.20]C3PO, 2020, CONV-ERT, 2021, CoV-Early (Gharbharan), 202230%1,275lownot evaluable mechanical ventilationdetailed resultsC3PO, 2020 1.49 [0.25; 9.02] 1.49[0.25; 9.02]C3PO, 202010%498NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-03-28 09:53 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 538,957 - roots T: 290